PREBOOK THIS REPORT - SAVE 10%

Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

TO BE PUBLISHED : Sep 2022 | Pages : 221

Up to $1050 off Prebook this report

THE GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SIZE WAS VALUED AT USD 7.81 BILLION IN 2021 AND IS EXPECTED TO REACH USD 12.46 BILLION BY 2027, GROWING AT A CAGR OF 8.09%.

The Global Psoriatic Arthritis Treatment Market Share, Size, & Trends Analysis Report by

  • Drug Class: TNF Inhibitors, Interleukin Inhibitors, NSAIDs, and Other class of Drugs
  • Disease Type: Spondylitis, Enthesitis, and Dactylitis
  • Gender Type: Men and Women
  • Age Group: 50 years and Below & 50 years and Above
  • Severity Type: Moderate, Mild, and Severe
  • Geography: North America (United States), APAC (China, Japan), and Europe (France, Germany, Italy, Spain & U.K.)

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

221 Pages

icon-table

9 Tables

icon-chart

160 Charts

icon-region

3 Regions

icon-country

8 Countries

icon-company

16 Companies

icon-market

6 Market Segment

PSORIATIC ARTHRITIS TREATMENT MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 12.46 Billion
Market Size (2021) USD 7.81 Billion
CAGR (2022-2027) 8.09%
Base Year 2021
Forecast Year 2022-2027
Market Segments Drug Class, Disease Type, Gender Type, Age Group, Severity Type, and Geography
Geographic Analysis North America, Europe, APAC
Countries Covered United States, France, Germany, Italy, UK, Spain, China, and Japan
TOTAL PREVALENT CASES IN 8MM (2021) 2,047,197
COUNTRY WITH HIGHEST PREVALENCE (2021) China (443,145)
COUNTRY WITH HIGHEST INCIDENCE (2021) China (108,316)
TOTAL PIPELINE ASSETS 26+ Assets (Phase III: 30.77%; Phase II: 23.08%)(Biologics: 69.23%; Small Molecules: 23.70%)
TOTAL CLINICAL TRIALS 150+ Clinical Trials (Completed: 36.36%; Recruiting (20.12%)
ANTICIPATED DRUG LAUNCHES IN NEAR FUTURE Bimekizumab; Tildrakizumab; Neihulizumab; SHR-1314 and Others

The global psoriatic arthritis treatment market is expected to reach USD 12.46 billion by 2027, from USD 7.81 billion in 2021,  growing at a CAGR of 8.09%. Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Psoriatic arthritis occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. It starts about 10 years after psoriasis develops for many people, but some develop PsA first or without ever developing or noticing psoriasis. PsA can occur at any age and affects men and women equally. In recent years, women have contributed more to the global psoriatic arthritis treatment market as they are at greater risk of developing psoriatic arthritis. According to estimates, in the European Union, PsA affects more than 2 million people, and in the United States, about 0.5 million.

The exact cause of PsA is not yet known. Family history plays a strong role; about 40% of those with the disease have a family member with psoriasis or arthritis. Risk factors can include obesity, severe psoriasis, nail disease, and trauma or deep lesions at sites of trauma.

Psoriatic Arthritis Diagnosis:
There’s no specific test to diagnose psoriatic arthritis. The symptoms are similar to other arthritic diseases such as rheumatoid arthritis, reactive arthritis, and gout. Imaging techniques such as X-rays, CT scans, ultrasound, MRI, and skin biopsies may all be used for diagnosis.

Psoriatic Arthritis Treatment:
Treatment depends on the extent of pain, swelling, and stiffness. Those with very mild arthritis may require treatment only when their joints are painful and may stop therapy when they feel better. The major types of treatment for psoriatic arthritis are Non-steroidal anti-inflammatory drugs such as ibuprofen (Motrin or Advil) or naproxen (Aleve) as initial treatment. If arthritis does not respond, disease-modifying anti-rheumatic drugs may be prescribed. These include sulfasalazine (Azulfidine), methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo), cyclosporine (Neoral, Sandimmune, Gengraf), and leflunomide. Sometimes combinations of these drugs may be used together. Azathioprine (Imuran) may help those with severe forms of PSA.

Other treatments include biologics, typically starting with TNF inhibitors such as adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade). Other biologics used for PsA include the IL-17A inhibitors secukinumab (Cosentyx) and ixekizumab (Taltz); IL-12/23 inhibitor ustekinumab (Stelara); IL-23 inhibitors risankizumab-rzaa (Skyrizi) and guselkumab (Tremfya) or other classes abatacept (Orencia). Newer oral medications, such as tofacitinib (Xeljanz), upadacitinib (Rinvoq), and apremilast (Otezla), have also been shown to be effective.

KEY HIGHLIGHTS

The psoriatic arthritis treatment market portfolio contains a total of 25+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for psoriatic arthritis are in the Phase III stage.  The emerging therapeutics for psoriatic arthritis include Bimekizumab, Tildrakizumab, SHR-0302, Neihulizumab, and many others. Launching these novel emerging drugs will shift the PsA treatment paradigm in the near future. With more than 25 molecules in various stages of development, it is expected that new vendors are likely to enter the industry with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating psoriatic arthritis.

Psoriatic Arthritis: Clinical Trials Scenario
 The clinical trial portfolio contains 150+ trials in various development phases. Most industry-sponsored drugs in active clinical development for PsA are in the Phase III stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for psoriatic arthritis have been in the late phase of development, with 58% of trials in Phase II/III & III and only 41% in Phase Phase I-II.

MARKET DRIVERS & TRENDS

Increasing Adoption of Biological Therapies
Biological therapies such as anti-tumor necrosis factor (TNF) and anti-interleukin antibodies are widely used in the psoriatic arthritis treatment market. With Stelara being biologic approved for PsA in 2013, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings. Many new classes of therapies are looking to enter the psoriatic arthritis treatment market over the next few years. The biologics such as interleukin inhibitors are making inroads into the psoriatic arthritis market owing to better clinical profile and convenient patient dosing.

Anticipated Launch of Emerging Drugs
A recent wave of biologic products prescribed for psoriatic arthritis treatment will likely create lucrative opportunities. Despite the plethora of therapies currently available to patients with psoriatic arthritis (PsA), there is still room for improvement within the psoriatic arthritis treatment market space.

Arizton anticipates the launch of five new agents among the 8MM, including two interleukins (IL) inhibitors (Bimekizumab; Tildrakizumab) and two oral Janus kinase (JAK) inhibitors (Filgotinib and SHR0302) and one oral tyrosine kinase 2 (TYK2) inhibitor (Deucravacitinib). Launching these late-stage drugs will create an opportunity for growth in the global psoriatic arthritis treatment market.

Focus on Novel Drugs with Novel Mechanism
Over the past seven years, agents that block inflammatory pathways other than tumor necrosis factor (TNF) represent new options for treating psoriasis arthritis (PsA). The therapeutic agents targeting the IL-23/IL-17 axis have been proven to be very effective in psoriatic arthritis, some are already in the therapeutic armamentarium, and others are in development. IL-23/IL-17 axis cytokines are essential players in the pathogenesis of psoriasis and PsA. Inhibition of IL-23 and IL-17 with monoclonal antibodies is a very effective therapy in the psoriatic arthritis treatment market. Over the next five years, Arizton expects to see a surge of innovation emerging from the research and development pipeline and a range of technology-enabled transformations that will expand the evidence-basis for interventions and bring measurable improvements to outcomes.

SEGMENTATION ANALYSIS

  • Drug Class: TNF-Alpha inhibitors account for a significant share of the global psoriatic arthritis treatment market. However, interleukin inhibitors are expected to be the fastest growing segment during the forecast period. Recently approved interleukin inhibitors such as Skyrizi (risankizumab-rzaa) and Cosentyx (Secukinumab) are expected to drive the global psoriatic arthritis treatment market during the forecast period.
  • Gender Type: Women accounted for a significant share of the global psoriatic arthritis treatment market under the gender type segment. This is because women have been at greater risk of psoriatic arthritis in recent years.
  • Disease Type: Enthesitis is expected to account for a significant share. However, Dactylitis is expected to be the fastest growing segment during the forecast period.
  • Age Group: People aged 50 years and below are expected to account for a significant share of the global psoriatic arthritis treatment market.
  • Severity Type: People with mild form are expected to account for a significant share of the global psoriatic arthritis treatment market under the severity type category. However, people with moderate form are expected to be the fastest growing segment during the forecast period.

GEOGRAPHICAL OUTLOOK

The U.S. dominates the global psoriatic arthritis treatment market by geography due to the healthcare affordability in the U.S., the knowledge and awareness amongst the people, and the technological advancement in this region. However, Germany is expected to grow faster with a high CAGR in the PsA drug industry due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter this region's psoriatic arthritis therapeutic landscape.

According to Arizton estimates, the prevalent cases of psoriatic arthritis were high in China, followed by Spain and the U.K. in 2020. The increasing prevalence of psoriatic arthritis is driving the growth of the psoriatic arthritis treatment market. According to estimates, more than two million people in European Union were affected by PsA in 2014.

COMPETITIVE LANDSCAPE

The global psoriatic arthritis treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating PsA. The U.S. Food and Drug Administration (FDA) approved the interleukin antibody Stelara (Ustekinumab) for treating psoriatic arthritis in 2013. Recently the FDA approved interleukins such as Skyrizi (risankizumab-rzaa) in 2022 and Cosentyx (secukinumab) in 2021 for treating PsA. Although generic products continue to capture significant psoriatic arthritis treatment market share, the arrival of biologics and other targeted therapies indicate a paradigm shift in this therapeutic space through the forecast period.

Companies such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Co Ltd, Biogen Inc, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Novartis are the major players in the global psoriatic arthritis treatment market. These players are focused on adopting growth strategies to strengthen their product portfolio. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global psoriatic arthritis treatment market.

The other prominent players operating in the psoriatic arthritis treatment market include Sun Pharmaceuticals, Bausch Health Companies Inc, Jiangsu HengRui Medicine Co. Ltd, Biocad Biopharmaceutical, Meiji Holdings Co Ltd, and Bio-Thera. These players are focused on R&D initiatives for developing technologically advanced and innovative psoriatic drugs and are also entering collaborations to maintain their position in the industry.

REPORT COVERS

  • Detailed overview of psoriatic arthritis treatment market, including disease definition, classification, diagnosis, and treatment pattern.
  • Overview of the global trends of the psoriatic arthritis treatment market in the eight major markets (8MM)
  • Historical, current, and projected patient pool of PsA in the eight major markets (8MM) for the 2018 – 2027 period
  • In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
  • Psoriatic arthritis treatment market share of the market players, company profiles, product specifications, and competitive landscape
  • Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
  • Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities.
  • Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for PsA across the complete product development cycle, including all clinical and non-clinical stages
  • Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for psoriatic arthritis across all clinical stages
  • Coverage of dormant and discontinued pipeline projects along with the reasons across PsA
  • Coverage of significant milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the psoriatic arthritis treatment market.

Frequently Asked Questions

How big is the global psoriatic arthritis treatment market?

The global psoriatic arthritis treatment market size is expected to reach USD 12.46 billion by 2027.

What is the growth rate of the global psoriatic arthritis treatment market?

The global psoriatic arthritis treatment market is growing with a CAGR of 8.09% from 2022-2027.

What factors drive the growth of the psoriatic arthritis treatment market?

The increasing adoption of biological therapies, the anticipated launch of emerging drugs, and the focus on novel drugs with novel mechanisms are prime factors driving the market.

Who are the leading vendors operating in the psoriatic arthritis treatment market?

Companies such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Co Ltd, Biogen Inc, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Novartis are the major players in the global psoriatic arthritis treatment market. These players are focused on adopting growth strategies to strengthen their product portfolio.

Which region holds the largest share in the global psoriatic arthritis treatment market?

The U.S. dominates the global psoriatic arthritis treatment market by geography due to the healthcare affordability in the U.S., the knowledge and awareness amongst the people, and the technological advancement in this region.

Download Free Sample

The global psoriatic arthritis treatment market is expected to grow at a CAGR of approximately 8.09% from 2022 to 2027.

The following factors are likely to contribute to the growth of the psoriatic arthritis treatment market during the forecast period:

  • Growing Adoption for Biological Therapies
  • Focus on Novel Drugs with Novel Mechanism

Base Year: 2021

Forecast Year: 2022-2027

The report considers the present scenario of the global psoriatic arthritis treatment market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

Key Vendors

  • AbbVie Inc.
    • Business Overview
    • Product Offerings
  • Johnson & Johnson
  • UCB SA
  • Amgen
  • Bristol-Myers Squibb
  • Pfizer
  • Eli Lilly and Company
  • Novartis

Other Prominent Vendors

  • Samsung Bioepis
  • Boehringer Ingelheim
  • Mylan
  • Merck & Co., Inc
  • Coherus BioSciences, Inc

Key Emerging Vendors with Late Stage Pipeline Drugs

  • Sun Pharmaceuticals
    • Company Overview
    • Product Offerings
  • Bausch Health Companies Inc
  • Jiangsu HengRui Medicine Co. Ltd
  • Biocad Biopharmaceutical
  • Meiji Holdings Co Ltd
  • Bio-Thera

Segmentation by Drug Class

  • TNF Inhibitors
  • Interleukin Inhibitors
  • NSAIDs
  • Other classes of Drugs

Segmentation by Disease Type

  • Spondylitis
  • Enthesitis
  • Dactylitis

Segmentation by Gender Type

  • Men
  • Women

Segmentation by Age Group

  • 50 years and Below
  • 50 years and Above

Segmentation by Severity Type

  • Moderate
  • Mild
  • Severe

Segmentation by Geography

  • North America
    • United States
  • APAC
    • China
    • Japan
  • Europe
    • U.K.
    • France
    • German
    • Italy
    • Spain

For more details, please reach us at enquiry@arizton.com

For more details, please reach us at enquiry@arizton.com

Select a license type that suits your business needs

single-user Single User Licence
$3000.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3400.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$4200.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1200.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date